NCT05604963 2026-03-05
HoT
University College, London
Phase NA Recruiting
Clinical Trials
18 trialsNCT07453225 2026-03-05
Empirical Radioactive Iodine Therapy in DTC
Assiut University
Phase 1/2 Not yet recruiting
NCT04321954 2026-02-27
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Massachusetts Eye and Ear Infirmary
Phase 2 Active not recruiting
NCT03416686 2026-02-25
METATHYRAF
Assistance Publique - Hôpitaux de Paris
Phase NA Active not recruiting
NCT05745363 2025-12-16
Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Completed
NCT05852223 2025-04-13
NePenThe
Istituti Clinici Scientifici Maugeri SpA
Phase 2 Recruiting
NCT04137185 2024-03-06
Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Completed
NCT04447183 2023-10-23
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Unknown
NCT04964284 2023-10-23
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT04858867 2023-10-10
RESET
Leiden University Medical Center
Phase NA Unknown
NCT05989425 2023-08-14
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Fudan University
Phase 2 Recruiting
NCT03048877 2023-04-12
Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase 3 Unknown
NCT03602495 2021-12-13
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Terminated
NCT01263951 2021-10-26
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
Thomas Jefferson University
Phase 2 Unknown
NCT04880798 2021-05-11
Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase NA Unknown
NCT01843062 2019-08-28
ASTRA
AstraZeneca
Phase 3 Terminated
NCT02586337 2019-05-21
Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Unknown
NCT02870569 2019-03-01
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Completed